Determining the optimal dose of haloperidol in first-episode psychosis

  title={Determining the optimal dose of haloperidol in first-episode psychosis},
  author={Piet Oosthuizen and Robin A Emsley and Jadri Turner and Natasha Keyter},
  journal={Journal of Psychopharmacology},
  pages={251 - 255}
Uncertainty exists as to the most appropriate dose of haloperidol in first-episode psychosis. This study set out to determine whether ultra-low doses of haloperidol could successfully treat patients with first-episode psychosis. Thirty-five patients with a first episode of psychosis were treated with haloperidol in an open label, fixed protocol over a 12-week period with doses restricted to 1 mg per day for the first 4 weeks. Twenty-nine (83%) remained on haloperidol after 12 weeks at a mean… 

Figures and Tables from this paper

Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Comparison of minimum doses of haloperidol with standard doses of risperidone and olanzapine on a 6-month open trial in first psychotic episode patients showed improvement in positive, negative and depressive symptoms and there were no differences in side-effects.
Treatment of first episode schizophrenia with low-dose haloperidol : a study in the Western Cape Province of South Africa
The principal finding was that the majority of subjects could be stabilized and maintained on very low doses of haloperidol and ratings for extra-pyramidal side-effects did not increase significantly from baseline over the duration of the study, except in the case of tardive dyskinesia (TD), where a substantial number of subjects developed TD within 12 months of starting treatment.
A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis.
This double-blinded, randomized controlled study compared the efficacy and tolerability of 2 vs. 8 mg/d of haloperidol over 6 wk in 40 subjects with first-episode psychosis, finding the low dose was better tolerated and effective in reducing the PANSS Total and subscale scores.
Pharmacotherapy of first-episode psychosis
Clinical guidelines for first-episode affective and non-affective psychosis, for patients with incomplete recovery or treatment resistance, for cases of emergency and for side effects associated with antipsychotic treatment are discussed and combined.
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review
There should be a clear recommendation of using lower doses of the antipsychotic medication in cases of FEP, and if no or minimal clinical improvement is found after 2 weeks of treatment, such patients may benefit from a change or augmentation of treatment.
The relationships between depression and remission in first-episode psychosis.
It is suggested that depressive symptoms in the acute psychotic episode differ from those in the post-psychotic period in terms of their phenomenology, temporal relationship to psychosis, and treatment response.
First-episode psychosis: An update
The literature on first-episode psychosis is reviewed and a resurgence of interest in psychosocial risk factors for the development of schizophrenia in the recent literature is highlighted.
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
It is suggested that when antipsychotics are reduced, it should be done gradually and in a hyperbolic manner (to reduce D2 blockade “evenly”): ie, reducing by one quarter (or one half) of the most recent dose of antipsychotic, equivalent to a reduction of 5 (or 10) percentage points of its D1 receptor blockade.
First-Episode Schizophrenia
Safety concerns in this group of young patients, in the beginning of their first psychotic episode, are a major issue as they are starting a journey of antipsychotic treatment that is likely to last for the remainder of their lives.


Optimal Haloperidol Dosage in First-Episode Psychosis
Many people suffering a first psychotic episode respond to haloperidol doses well below levels in common use, and subjects whose optimal dose was 2 mg daily showed the greatest improvement.
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
Of the 58 patients exposed only to NT dosages of haloperidol, 72% clinically recovered within the 5-week trial, and higher dosages given to 47 patients did not lead to greater improvement in measures of psychosis, but did produce slightly greater declines in measuresof hostility.
A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.
A 20-mg/d dose of haloperidol may have substantial "psychotoxic" effects by the second week of treatment, therefore, the group receiving the 20- mg dose deteriorated significantly with regard to Brief Psychiatric Rating Scale ratings of Withdrawal-Retardation as well as akinesia and akathisia ratings.
Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
The results of this study show that the relatively low and fixed dose of 60 mg of HD every fourth week was superior to placebo in preventing relapse in schizophrenia.
Haloperidol plasma levels and dose optimization.
Haloperidol plasma levels that substantially exceed 18 ng/ml may be countertherapeutic for schizophrenic patients, and increases in dose beyond this level are not efficacious for patients who have not responded to lower doses.
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Sertindole is a new antipsychotic agent effective for the treatment of both the positive and negative symptoms of schizophrenia, with motor side effects that are indistinguishable from those associated with placebo.
Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.
Despite the fact that very little dyskinetic symptomatology developed in the sample as a whole, the low-dose treatment appeared to have a significant advantage in producing fewer early signs of tardive dyskinesia.
Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group.
  • R. Emsley
  • Psychology, Medicine
    Schizophrenia bulletin
  • 1999
The severity of extrapyramidal symptoms and the use of antiparkinsonian medications were significantly lower in patients receiving low doses of risperidone or haloperidol than high doses of these antipsychotics.
Course of treatment response in first-episode and chronic schizophrenia.
The results suggest that maximum symptomatic improvement occurs within the first 6 months of treatment and that disease progression may blunt treatment efficacy in both first-episode and chronic schizophrenia.